Drug Trial Radar · NCT06990984
A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)
Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Jun 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Thiogenesis Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to investigate oral TTI-0102 to evaluate its pharmacokinetics, safety, and preliminary efficacy in patients with Leigh syndrome spectrum, in three sequences. First sequence will be placebo-controlled and include 12 adolescents and adults weighing more than 40 kg. Second sequence will be open-label and include 3 adults and 3 children weighing 25-40 kg. Third sequence will also be open-label and will include 3 children weighing 20-25 kg. The main questions clinical trial aims to answer are: * Characterize the relationship between TTI-0102 drug levels by measuring 1. cysteamine pharmacokinetic (PK) parameters 2. pharmacodynamic (PD) efficacy measures * Generate a population PK model and determine dose level for later dosing groups * collect data to inform the design of a subsequent phase 2b/3 study of TTI-0102 in this patient population Participants will be asked to: * Take the study drug twice daily for 12 weeks * Visit the clinic for checkups and testing 7 times in total: once prior to study drug dosing, then 5 times over the 12-week treatment period and one more time a month after the last study drug dose.
Conditions
- Leigh Syndrome
Interventions
TTI-0102: cysteamine-pantetheine disulfideDrug
TTI-0102: cysteamine-pantetheine disulfide, powder for dissolution in water for oral administration
D-MannitolDrug
D-Mannitol
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK: plasma cysteamine (Tmax)Time frame: Baseline (Day 1) to end of treatment (Day 84)
- PK: plasma cysteamine (Cmax)Time frame: Baseline (Day 1) to end of treatment (Day 84)
- PK: plasma cysteamine (Cmin)Time frame: Baseline (Day 1) to end of treatment (Day 84)
- PK: plasma cysteamine (PK curve)Time frame: Baseline (Day 1) to end of treatment (Day 84)
- PK: plasma cysteamine (AUC)Time frame: Baseline (Day 1) to end of treatment (Day 84)
- PD: plasma glutathioneTime frame: Baseline (Day 1) to end of treatment (Day 84)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.